权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targets, Structures and Drugs (TSD)

靶点、结构和药物 (TSD)

基本信息

批准号：
10434761
负责人：
Mingji Dai
金额：
$ 4.23万
依托单位：
PURDUE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-05-08 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10434761
关键词：
Animal Model Animals Antineoplastic Agents Area Award Basic Science Biological Products Biological Response Modifier Therapy Biology Biophysics Cancer Biology Cancer Center Support Grant Cancer Model Canis familiaris Chemical Structure Chemicals Clinical Sciences Clinical Trials Collaborations Competence Cryoelectron Microscopy Development Drug Design Drug Targeting Electrons Evaluation Faculty Faculty Recruitment Funding Goals Grant Health Human Immunologics Indiana University Cancer Center Institution Investigation Investigational Therapies Knowledge Lead Leadership Legal patent Malignant Neoplasms Methodology Mission Modality Modeling Molecular Molecular Structure Movement NCI Center for Cancer Research Organic Synthesis Paper Participant Peer Review Pharmaceutical Chemistry Pharmaceutical Preparations Phase Preclinical Testing Process Program Research Project Grants Publications Publishing Purdue Cancer Center Research Research Personnel Research Support Resolution Scientist Secure Structure Synthesis Chemistry Testing Therapeutic Training Translating United States National Institutes of Health Universities Validation anti-cancer anticancer research base biological development cancer clinical trial cancer therapy canine model clinical application clinical center comparative computerized tools drug development drug discovery high throughput screening human disease inhibitor innovation inter-institutional interest lead optimization member new technology novel novel therapeutics preclinical evaluation preclinical study programs protein structure rational design recruit research clinical testing small molecule structural biology symposium targeted agent targeted treatment therapeutic development tool tumor

项目摘要

Targets, Structures and Drugs (TSD) Research Program Project Summary The mission of the newly formed Targets, Structures, and Drugs (TSD) Program is to accelerate the development of novel therapies for cancer treatment through a pipeline that identifies lead compounds or macromolecular target structures, and progresses their development by medicinal chemistry lead optimization, rational design, and preclinical evaluation using animal models, including naturally occurring canine models that are highly reflective of human disease. Purdue Center for Cancer Research (PCCR) academic leadership in drug discovery is characterized by development of novel inhibitors for targets validated by PCCR scientists. TSD's 50 Program members have shepherded 11 PCCR compounds into human clinical trials and 37 compounds (up from 24 at the last review) into preclinical evaluation, including a total of 22 canine studies of PCCR leads and novel technologies. Our goal the next grant cycle is to further enhance drug development by continuing to enhance therapeutic lead development. The TSD is led by three co-leaders: David Thompson (Lead, Medicinal Chemistry cluster), Deborah Knapp (Lead, Target Validation cluster), and John Tesmer (Lead, Chemical and Structure Biology cluster). The TSD developmental pipeline is further strengthened by the strategic addition of 24 new members since the last review, giving the TSD Program robust coverage in each phase of the drug development pipeline. Members of the TSD Program are active participants in the NCI Experimental Therapeutics – Chemical Biology Consortium (Thompson, Director), NCI Comparative Oncology Clinical Trials Consortium (Childress, Purdue Director), DARPA Make It (Thompson, co- Director), as well as NIH T32 Training Grants in Molecular Biophysics - (Tesmer, Director) and Drug Discovery (Dai, co-Director). Over this last funding period, TSD faculty have secured $9.7 million in peer-reviewed cancer- related support; have published 505 peer-reviewed articles, (25 % high-impact) with 14% intra-programmatic and 15% inter-programmatic collaborations (49% inter-institutional). Further, TSD faculty translate their research into deliverables, including 53 patents and 5 companies during this latest funding period. To facilitate our goals of advancing PCCR lead compounds, the TSD program plans to: (1) strategically deploy programmatic funds to nucleate and support new inter- and intra-programmatic collaborations; (2) leverage Purdue's strength in cryo-electron microcopy (cryo-EM) to enhance structure-based drug design and target validation; (3) further develop scalable automated continuous synthesis of PCCR leads enabled by Boilermaker Health Innovations (BHI); (4) expand lead testing in canine spontaneous cancer models; and (5) inspire the continuing development of scientific leaders in cancer research through innovative training. We will further these goals by recruiting leading scientists, particularly in the areas of drug discovery, chemical biology, and cryo-EM and continue cultivating a transdisciplinary culture through TSD Program gatherings and by hosting targeted symposia of interest to our faculty.

目标，结构和药物（TSD）研究计划